<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
<ATC code="G03AA08" />
<ATC code="G03AA04" />
<ATC code="G03AB01" />
<ATC code="G03AA13" />
<ATC code="G03AA05" />
<ATC code="G03AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatoxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GEMFIBROZIL" rxcui="4719">
<ATC code="C10AB04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>162-DASABUVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MITOTANE" rxcui="7004">
<ATC code="L01XX23" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
